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Abstract
In high-risk individuals participating in a pancreatic cancer surveillance program, worrisome features warrant for intensified 
surveillance or, occasionally, surgery. Our objectives were to determine the patient-reported burden of intensified surveillance 
and/or surgery, and to assess post-operative quality of life and opinion of surgery. Participants in our pancreatic cancer sur-
veillance program completed questionnaires including the Cancer Worry Scale (CWS) and the Hospital Anxiety and Depres-
sion Scale (HADS). For individuals who underwent intensified surveillance, questionnaires before, during, and ≥ 3 weeks 
after were analyzed. In addition, subjects who underwent intensified surveillance in the past 3 years or underwent surgery 
at any time, were invited for an interview, that included the Short-Form 12 (SF-12). A total of 31 high-risk individuals were 
studied. During the intensified surveillance period, median CWS scores were higher (14, IQR 7), as compared to before 
(12, IQR 9, P = 0.007) and after (11, IQR 7, P = 0.014), but eventually returned back to baseline (P = 0.823). Median HADS 
scores were low: 5 (IQR 6) for anxiety and 3 (IQR 5) for depression, and they were unaffected by the intensified surveil-
lance period. Of the 10 operated patients, 1 (10%) developed diabetes and 7 (70%) pancreatic exocrine insufficiency. The 
interviews yielded median quality-of-life scores comparable to the general population. Also, after surgery, patients’ attitudes 
towards surveillance were unchanged (5/10, 50%) or became more positive (4/10, 40%). Although patients were aware of 
the (sometimes benign) pathological outcome, when asked if surgery had been justified, only 20% (2/10) disagreed, and 
all would again have chosen to undergo surgery. In conclusion, in individuals at high risk for pancreatic cancer, intensified 
surveillance temporarily increased cancer worries, without affecting general anxiety or depression. Although pancreatic 
surgery led to substantial co-morbidity, quality of life was similar to the general population, and surgery did not negatively 
affect the attitude towards surveillance.
Keywords Psychology · Patient-reported outcome measures · Resection · Quality of life · Pancreatic cancer · Surveillance
Introduction
Pancreatic cancer surveillance aims to detect pancreatic 
ductal adenocarcinoma (PDAC) or its precursors in a 
resectable stage. Because a non-invasive and accurate 
diagnostic test is lacking, and the incidence of PDAC 
in the general population is low [1], surveillance is only 
recommended for selected individuals with an increased 
lifetime risk [2]. For this group, magnetic resonance 
imaging (MRI) and/or endoscopic ultrasonography 
(EUS) at twelve-month intervals is advised [2]. The goal 
is to detect stage one PDAC or, preferably, high-grade 
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precursor lesions [2]. However, especially in small 
lesions, imaging techniques may not be able to distin-
guish malignancy and high-grade precursors from benign 
disease [3, 4].
As a consequence, in large prospective surveillance 
programs, up to 50% of patients undergo surgery for 
low-grade or non-dysplastic lesions [5–7]. And despite 
recent advances, pancreatic surgery is still associated with 
substantial morbidity and mortality [8]. Cases have been 
reported of high-risk individuals experiencing nearly fatal 
complications after resection of a lesion that did not har-
bor malignancy or high-grade dysplasia [9]. It may be 
argued that surgery was unjustified in these cases, as the 
goals of surveillance were not met. On the other hand, we 
do not know the progression rate of pancreatic lesions in 
high-risk individuals, and what the outcomes would have 
been, had surgery been postponed. It is unknown how 
high-risk individuals perceive this dilemma and whether 
they find the burdens of surgery to outweigh the gains.
To prevent surgery for benign disease, individuals with 
lesions of unknown relevance are usually subjected to 
an intensified surveillance period, with shortened inter-
vals of three or six months [2]. During this time, patients 
are burdened with the knowledge of having a lesion of 
unclear etiology, and with undergoing additional visits 
and investigations. Reinforced by the oftentimes strong 
family history of PDAC, this seems an obvious cause 
for worries. While earlier studies have shown that, on 
average, the psychological burden of surveillance seems 
acceptable [10], the psychological impact of a period of 
intensified surveillance has never been assessed.
Therefore, the aims of this study were to assess: (1) 
the patient-reported impact of intensified surveillance 
on cancer worries, anxiety, and depression; and (2) the 
patient-reported burden of surgery, and the post-operative 
quality of life and opinion of surgery.
Methods
Design of the surveillance study
This study is part of the ongoing Dutch familial pancreatic 
cancer surveillance study (FPC-study). This prospective 
study, started in 2006, is performed in three university hos-
pitals and investigates the effectiveness of pancreatic cancer 
surveillance in high-risk individuals. Eligible for surveil-
lance are asymptomatic individuals with an estimated 10% 
or greater lifetime risk of PDAC, encompassing carriers of 
a mutation in a known pancreatic cancer susceptibility gene 
and individuals without a known gene mutation but a strong 
family history of PDAC, defined as familial pancreatic can-
cer (FPC) kindreds. Complete inclusion criteria are listed 
in Box 1. The minimal age for inclusion was 45 years until 
2013 and 50 thereafter, or ten years younger than the age of 
the youngest relative with PDAC, whichever of the two ages 
was the lowest. Surveillance was stopped at the age of 75. A 
clinical geneticist evaluated all individuals prior to enroll-
ment. If a mutation in a known PDAC susceptibility gene 
was found (see Box 1), only family members who tested 
positive were enrolled.
Surveillance procedures and clinical management
The study procedures have been described previously 
[11–13]. In summary, at baseline and follow-up visits, both 
EUS and MRI were performed. Since 2009, participants 
have been invited to complete psychological questionnaires 
following each surveillance visit [12, 14, 15]. Clinical man-
agement was decided upon by a multidisciplinary expert 
panel, consisting of endosonographists, radiologists, sur-
geons, and pathologists. The policy was as follows:
(1) Regular surveillance after twelve months in case of no 
abnormalities, minor signs of chronic pancreatitis, or 
cystic lesions without worrisome features.
Box 1  Inclusion criteria for the Dutch Familial Pancreatic Cancer Surveillance Study (FPC-study). Harinck et al. [11]
BRCA Breast Cancer, CDKN2A Cyclin-Dependant Kinase Inhibitor 2A, LKB1/STK11 Liver Kinase B1/Serine/Threonine Kinase 11, MLH MutL 
Homolog, MSH MutS Homolog, PDAC Pancreatic Ductal Adenocarcinoma, TP53 Tumor Protein 53
1. CDKN2A gene mutation, regardless of PDAC family history
2. Peutz-Jeghers syndrome (proven LKB1/STK11 gene mutation or clinical diagnosis), regardless of PDAC family history
3. BRCA2, BRCA1, TP53, MLH1, MSH2 or MSH6 gene mutation, and ≥ 2 relatives with PDAC, of which ≥ 1 histologically proven
4. First-degree relatives of a family member with PDAC, in families with ≥ 1 histologically proven PDAC, and either:
 (a) PDAC in ≥ 2 relatives who were first-degree relatives to each other
 (b) PDAC in ≥ 3 relatives, who were first or second-degree relatives to each other
 (c) PDAC in ≥ 2 relatives, of which ≥ 1 was under 50 years of age, who were first or second-degree relatives to each other
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(2) Intensified surveillance after three or six months when a 
worrisome lesion was detected not warranting immedi-
ate surgery. This included indeterminate solid lesions; 
cystic lesions with a worrisome feature but no high-
risk stigmata (e.g. a thickened enhanced cyst wall, cyst 
growth of 5 mm/2 years, or mural nodule < 5 mm) [16]; 
and a dilated main pancreatic duct of < 10 mm without 
a visible mass. If a lesion remained stable in size and/
or was no more considered suspicious for malignancy, 
the surveillance interval was reversed to twelve months.
(3) Surgical resection was performed if the expert panel 
agreed on suspicion for malignancy, based on positive 
cytology; a main pancreatic duct dilation ≥ 10 mm and/
or an abrupt caliber change; a cystic lesion with high-
risk stigmata or ≥ two worrisome features [16]; or a 
solid lesion.
Patient selection
A flow chart of the patient selection process is shown in 
Fig. 1. We identified all individuals in whom a worrisome 
lesion had been detected for which they had undergone 
intensified surveillance and/or surgical resection by January 
2018. These patients were classified into three subcohorts:
(1) The intensified surveillance questionnaire subcohort 
consisted of those who had returned to regular intervals 
and who had completed at least two out of the three 
questionnaires: (1) while under regular surveillance, 
before the decision to intensify surveillance; (2) during 
the intensified surveillance period; and (3) ≥ 3 weeks 
after the decision to return to regular intervals.
(2) The intensified surveillance interview subcohort con-
sisted of those who had returned to regular intervals 
and consented to an interview. To reduce recall bias, 
this was restricted to those who underwent intensified 
surveillance within the last three years. Individuals 
could be included in both the questionnaire and the 
interview subcohort.
(3) The surgical interview subcohort consisted of those 
who underwent surgical resection (with or without 
prior intensified surveillance period) and consented to 
an interview. For these interviews, inclusion was not 
restricted and all who underwent surgery and were alive 
were invited.
Psychological questionnaires
We investigated the questionnaire outcomes regarding can-
cer-related worries, general anxiety, and depression. These 
were measured using the Cancer Worry Scale (CWS) and the 
Hospital Anxiety and Depression Scale (HADS). The CWS 
is a validated tool containing eight items, of which the total 
score ranges from eight to 32. A score of ≥ 14 is indicative 
of high levels of cancer worries [17, 18]. The HADS is a 
validated tool consisting of two subscales: one for general 
anxiety (HADS-A) and one for depression (HADS-D). Each 
contains seven items and scores for each range from zero to 
21 [19–21]. A score of ≥ 8 is considered to reflect elevated 
levels of general anxiety and depression [21].
Semi‑structured interviews
Patients were interviewed by telephone by the same medical 
doctor (AK). The interviews were semi-structured, meaning 
there was a structure of topics that needed to be covered 
using pre-defined, open-ended questions. If deemed appro-
priate, the interviewer could deviate from the structure in 
order to follow certain topics [22]. The interviews included 
questions on their general opinion of surveillance, and 
specifically on either the intensified surveillance period or 
surgery (complete interview structures in the Supplemen-
tary Information). The interview for surgical patients also 
included the Short Form-12 (SF-12), a validated question-
naire to measure physical and mental quality of life [23, 
24]. This score ranges from zero to 100, with higher scores 
indicating better quality of life, and a score of 50 represent-
ing the mean in the general population [24, 25].
The audiotaped interviews were transcribed and analyzed 
using conventional content analysis [26]. Two independ-
ent reviewers (KAO and AK) interpreted and labelled the 
responses using a predefined codebook. The codebook con-
tained response categories that were drawn up based on the 
Fig. 1  Flow-chart of patient selection and response rate per studied 
subcohort. Note: *Three patients underwent two separate intensified 
surveillance periods, separated by several years, leading to a return to 
regular intervals in one period, and to surgery in the other
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expected range of answers, both positive and negative. Both 
reviewers labelled the first interview of both the intensified 
surveillance interview and the surgery interview, and then 
discussed discrepancies to reach consensus on how to label 
responses. After labelling the first half of the interviews, 
another interview of each type was labelled by each reviewer 
and then discussed before the remainder was labelled.
Statistical analysis
Descriptive statistics are presented as percentages, or as 
medians with interquartile range or means with standard 
deviation, depending on the distribution of the data. Cohen’s 
kappa was performed on the interview results to assess inter-
rater agreement. The Cronbach’s alpha on internal consist-
ency was performed on the CWS, the HADS-A and HADS-
D to assure reliability. All three showed good internal 
consistency (α > 0.8) at each of the three time points (before, 
during and after intensified surveillance). Changes in CWS, 
HADS-A and HADS-D scores could not be analyzed with 
a linear mixed model, because the underlying assumption 
that missing questionnaires were missing at random could 
not be made. Instead, these changes were assessed using 
the Wilcoxon signed rank test, which was performed on 
the three different combinations of repeated measurements 
(before versus during intensified surveillance, during versus 
Table 1  Characteristics of 
intensified surveillance patients 
and surgical patients
Values presented as n (%) unless otherwise indicated
BRCA, Breast Cancer, CDKN2A, Cyclin-Dependant Kinase Inhibitor 2A, FAMMM familial atypical mul-
tiple mole melanoma, HBOC hereditary breast and ovarian cancer, IQR interquartile range, LKB1/STK11 
Liver Kinase B1/Serine/Threonine Kinase 11, PDAC pancreatic ductal adenocarcinoma, TP53 Tumor Pro-
tein 53
Patient characteristics Intensified surveillance Surgery
Questionnaires 
(n = 20)
Interviewees 
(n = 8)
Inter-
viewees 
(n = 10)
Age at start surveillance, median (IQR), y 51 (11) 53 (15) 46 (11)
Time under surveillance, median (IQR), m 99 (40) 68 (81) 88 (72)
Male gender 7 (35) 4 (50) 5 (50)
Caucasian 18 (90) 8 (100) 9 (90)
Risk category
 Familial Pancreatic Cancer kindred 8 (40) 5 (63) 7 (70)
 Mutation carrier 12 (60) 3 (38) 3 (10)
 CDKN2A (FAMMM syndrome) 7 (35) 2 (25) 1 (10)
 BRCA2 + 2 affected family members (HBOC) 3 (15) 1 (13) 1 (10)
 STK11/LKB1 (Peutz-Jeghers syndrome) 1 (5) 0 (0) 1 (10)
 TP53 (Li Fraumeni syndrome) 1 (5) 0 (0) 0 (0)
Number of relatives with PDAC
 0 2 (10) 1 (13) 1 (10)
 1 or 2 10 (50) 3 (38) 3 (30)
 3 or more 8 (40) 4 (50) 6 (60)
Age youngest relative with PDAC, median (IQR) 56 (16) 61 (29) 51 (11)
Personal history of non-pancreatic malignancy 12 (60) 5 (63) 3 (30)
Education level
 Low (only primary or secondary school) 5 (25) 2 (25) 3 (30)
 Medium (education after secondary school) 5 (25) 3 (38) 4 (40)
 High (college or university) 10 (50) 3 (38) 3 (30)
Has children
 Yes 17 (85) 6 (75) 6 (60)
 No 2 (10) 0 (0) 1 (10)
 Unknown 1 (5) 2 (25) 3 (30)
Married or co-habiting
 Yes 13 (65) 4 (50) 7 (70)
 No 6 (30) 2 (25) 0 (0)
 Unknown 1 (5) 2 (25) 3 (30)
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after, and before versus after). We corrected for this multiple 
testing of each scale by applying a Bonferroni correction 
(0.05/3). A P value of < 0.017 was considered statistically 
significant. To compute the physical and mental compo-
nent summaries (PCS and MCS) of the SF-12, regression 
weights were used that were derived from normative data of 
the Dutch general population, using the orthogonal rotation 
method [24]. We used SPSS Statistics 22 (IBM Corporation, 
Armonk, New York, USA) for all analyses.
Results
Response rates and patient characteristics
By January 2018, 298 individuals were under pancreatic 
cancer surveillance, of whom 36 (12%) had been subjected 
to a period of intensified surveillance not leading to surgery 
or a diagnosis of PDAC (Fig. 1). In five individuals, this took 
place prior to commencement of the questionnaire study in 
2009. Of the remaining 31, 20 (65%) had completed ques-
tionnaires on at least two of the three occasions (before, 
during, and after intensified surveillance), and were included 
in the questionnaire subcohort. Twelve individuals under-
went intensified surveillance within the last three years and 
were invited for an interview. Two (17%) did not respond, 
two (17%) declined participation without explanation, and 
eight individuals (67%) consented. Five of the eight were 
also included in the questionnaire subcohort. Therefore, in 
total, 23 out of 31 (74%) eligible intensified surveillance 
participants were studied.
Of the 15 patients who underwent surgery, four died of 
PDAC. Of the 11 living individuals, one declined partici-
pation without explanation and ten (91%) consented to an 
interview. Two of these patients were also included in the 
questionnaire subcohort (for an intensified surveillance 
period that was at least a year apart and independent from 
their surgery). Altogether, 31 individuals were studied: 12 
(39%) male; median age 52 (IQR 13) years; 16 (52%) famil-
ial pancreatic cancer kindreds; and 15 (48%) gene mutation 
carriers. Baseline characteristics of the three subcohorts are 
presented in Table 1.
Cancer worries, Anxiety, and Depression
Median scores are visualized in Fig. 2. Cancer worries were 
significantly higher during intensified surveillance (median 
14, IQR 7) than before (median 12, IQR 9, P = 0.007), and 
decreased significantly after (median 11, IQR 7, P = 0.014). 
After surveillance resumed at regular intervals, cancer wor-
ries returned to baseline levels (P = 0.823). Overall anxiety 
(median 5, IQR 6) and depression (median 3, IQR 5) scores 
were low and did not change during or after intensified sur-
veillance (all P values > 0.017).
General opinion on surveillance
The results of the 18 interviews on surveillance are pre-
sented in Table 2. Interviewees reported their motivation 
to participate in surveillance to be: achieving early detec-
tion of pancreatic cancer (15/18, 83%), contributing to 
research (9/18, 50%), improving prognosis in the future for 
themselves and/or younger family members (4/18, 22%), 
and making them feel in control or proactive (3/18, 17%). 
Their preferred surveillance interval was twelve months 
(8/18, 44%), twelve months but shorter if abnormalities are 
detected, in concordance with the current protocol (4/18, 
22%), or six months (4/18, 22%). One patient preferred to 
leave it up to the specialist’s opinion and another to decide 
after discussion with the specialist. The vast majority (17/18, 
94%) wanted long-term surveillance, either forever (8/18, 
44%) or until it is stopped by the program (9/18, 50%). 
Regarding surveillance modalities, EUS was preferred over 
Fig. 2  Median Cancer Worry Scale (CWS) and Hospital Anxiety 
and Depression Scale (HADS) scores before, during, and ≥ 3  weeks 
after an intensified surveillance period. Note: Graph displays median 
scores of all patients per time point, statistical analyses were per-
formed on paired measurements only (before versus during, during 
versus after, before versus after, n = 12 for all three analyses). Sig-
nificant differences marked with *, non-statistically significant differ-
ences with ns
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MRI by 50% (9/18), MRI over EUS by 11% (2/18), and 28% 
(5/18) did not have a preference.
Intensified surveillance interviews
The inter-rater agreement of the first interview was good 
(κ 0.695, P < 0.001) and improved to outstanding half-
way (κ 0.835, P < 0.001). Intensified visits were experi-
enced as conveying more anxiety or nervousness by three 
individuals (38%), as more burdensome by two (25%), 
and as no different from regular follow-up by two (25%). 
One patient reported not to have experienced more anxi-
ety, but even to be grateful to have undergone additional 
imaging that provided swift reassurance. According to 
the participants, the regular follow-up schedule was 
resumed because the lesion remained stable in size (four 
individuals, 50%), because the lesion was determined to 
be benign (one, 13%), and for reasons unknown to the 
participant (three individuals, 38%). Five (63%) individu-
als still worried over the detected abnormality, despite 
having returned to regular intervals. Two patients judged 
the intensified surveillance period as something positive 
(25%), two as neutral (25%), three as negative but neces-
sary (38%), and one as just negative (13%). The majority 
(75%) of patients claimed that their general opinion of 
surveillance did not change by undergoing a period of 
intensified surveillance. One (13%) now thought more 
positively towards surveillance and one more negatively. 
Three individuals (38%) actively worried about their fam-
ily members, and none would discourage family members 
to undergo surveillance.
Surgery interviews
The ten interviewed surgical patients were operated at a 
mean age of 51 (SD 8.6) years. They were interviewed a 
median of 43 (IQR 63) months after surgery. Again, the 
inter-rater agreement of the surgery interview was good at 
first (κ 0.725, P < 0.001) and outstanding halfway (κ 0.831, 
P < 0.001). The complete results of the interviews are listed 
in Table 3.
Of the surgical patients, two individuals (20%) judged 
their immediate recovery after surgery as good (fast, no 
complications), five individuals (50%) as fair (longer recov-
ery time than anticipated and/or minor complications), and 
three individuals (30%) as poor (major complications). 
At the time of interview, four (40%) had returned to their 
preoperative health level (median 43 months after surgery, 
IQR 35) and five individuals (50%) had not completely 
recovered (median 24 months after surgery, IQR 97). One 
patient had developed diabetes mellitus requiring insulin 
therapy, and seven (70%) had developed exocrine pancreatic 
Table 2  Interview results 
of general questions on 
surveillance
Values presented as n (%)
EUS endoscopic ultrasonography, MRI magnetic resonance imaging
Intensified
surveillance
Surgery Total
n = 8 n = 10 N = 18
Motivation to participate (could be more than one)
 To detect pancreatic cancer early 8 (100) 7 (70) 15 (83)
 To help scientific research 6 (75) 3 (30) 9 (50)
 To improve prognosis 1 (13) 3 (30) 4 (22)
 To have the feeling to have influence/control 0 (0) 3 (30) 3 (17)
Preferred surveillance interval
 12 months 3 (38) 5 (50) 8 (44)
 12 months but shorter if abnormalities present 1 (13) 3 (30) 4 (22)
 6 months 2 (25) 2 (20) 4 (22)
 Decide together with doctor 2 (25) 0 (0) 2 (11)
Preferred surveillance duration
 Forever 4 (50) 4 (40) 8 (44)
 Until a certain age 1 (13) 0 (0) 1 (6)
 Until no longer required by the surveillance program 3 (38) 6 (60) 9 (50)
Preferred imaging modality
 EUS 4 (50) 5 (50) 9 (50)
 MRI 2 (25) 0 (0) 2 (11)
 No preference 2 (25) 3 (30) 5 (28)
 Missing 0 (0) 2 (20) 2 (11)
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insufficiency, leading to digestive complaints and changes 
in fecal consistency requiring dietary changes and enzyme 
replacement therapy at every meal.
Patients’ interpretation of the pathological outcome 
showed moderate agreement (κ 0.500, P = 0.007) with the 
actual pathology report. The one person with pancreatic 
cancer (more specifically, intraductal papillary mucinous 
neoplasia-associated invasive carcinoma), was unaware of 
this outcome, despite detailed explanation while admitted 
to the hospital post-surgery. The majority (seven individu-
als, 70%) deemed surgery to have been justified. The two 
who did not, had benign pathological outcomes. When asked 
if they would choose surgery again—if presented with the 
same situation—all patients affirmed, including the three 
who believed they had undergone surgery for benign disease, 
the three who judged surgery as something negative, and 
the patient who was unaware of the malignant pathological 
outcome.
Their general opinion of surveillance was unchanged by 
surgery (five individuals, 50%) or positively affected (four 
individuals, 40%), but never negatively. Only one person 
(who had developed major complications, including a hepa-
ticojejunostomy stenosis with recurrent cholangitis, and 
abdominal abscesses requiring several re-admissions) would 
not actively recommend surveillance to family members, but 
would leave the choice up to them. All other patients would 
recommend surveillance.
Quality of life after surgery
Median quality-of-life scores (median 43 months after sur-
gery, IQR 6) were 56 (IQR 5) for the physical component 
summary, and 52 (IQR 7) for the mental component sum-
mary. These scores were comparable to age-matched norma-
tive data from the Dutch general population [24].
Discussion
This is the first study that specifically investigates the bur-
den of intensified surveillance and surgery, as perceived by 
high-risk individuals participating in a pancreatic cancer 
surveillance program. It addresses several potential harms 
of surveillance, including false positive test results; com-
plications and side effects of diagnostic investigations and 
treatment; overtreatment; and the associated psychological 
burden [27]. Assessment and avoidance of harm is of great 
importance in cancer screening [28]. This holds especially 
true for pancreatic cancer surveillance, as benefits in reduc-
ing cancer-related mortality are still unproven, and treatment 
is associated with significant morbidity or even mortality 
[8]. Additionally, indeterminate lesions are frequently found 
(in our cohort in 16%), making assessment of the burden of 
intensified surveillance highly relevant.
Previously, results from our and other groups demon-
strated, on average, low cancer worries, general anxiety, 
depression and general distress within surveillance cohorts 
of high-risk individuals [14, 15, 29–32]. This was recently 
confirmed in a systematic review [10]. Earlier, we described 
an increase in CWS score of six individuals under intensified 
surveillance, but this did not reach statistical significance 
[12].
Presently, we were able to analyze a larger number of 
individuals and demonstrated that intensified surveillance 
leads to a temporary increase of cancer worries reaching the 
cut-off value for a high level of fear. Indeed, it is understand-
able that finding an indeterminate lesion and undergoing 
additional investigations lead to an increase in worries in 
individuals with high PDAC risk. It is reassuring that this 
increase is relatively small (median of two on a scale from 
8 to 32), and temporary. In the interviews, five out of eight 
individuals reported to still regularly worry about the abnor-
mality that was found, despite having returned to regular 
intervals. However, their CWS scores at that time point were 
relatively low, suggesting these worries are also moderate 
and do not interfere with their daily functioning. Overall, 
the burden of intensified surveillance seems tolerable, which 
renders the decision to closely monitor an indeterminate 
lesion more justified and much preferred over surgery, with 
its associated risks and the possibility of overtreatment. This 
is especially true given the result that of 48 individuals with 
a worrisome lesion, only two were diagnosed with a malig-
nancy or pathologically proven high-grade dysplasia.
After surgery, the pathological outcomes of the major-
ity (80%) of individuals did not fulfill formal surveillance 
goals (seven resected with only low-grade dysplasia, one 
non-required resection for autoimmune pancreatitis). There 
is still no consensus amongst experts whether these cases 
should be considered a success of surveillance or as over-
treatment [2]. Nevertheless, most patients deemed surgery to 
have been justified and all of them would likely or definitely 
choose to undergo surgery again. This may be a reflection of 
high-risk individuals being highly motivated to participate 
in surveillance and undergo treatment, driven by a strong 
will to prevent dying of pancreatic cancer. It may also have 
been influenced by cognitive dissonance. Cognitive disso-
nance is a psychological discomfort or tension that can arise 
when there is a discrepancy between an individual’s actions 
and attitude [33]. This can occur especially in situations in 
which the action is irreversible and was the individual’s own 
choice, and when there are negative outcomes. In order to 
reduce this psychological discomfort, individuals may adjust 
their attitudes to support their initial actions by increasing 
their preference for the selected option [34]. In addition, 
participants’ positive opinion of surgery may be attributable 
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to the participants being insufficiently aware of the patho-
logical outcome, given the moderate agreement between the 
diagnosis according to the pathologist and the patient.
Another finding of insufficient awareness was the fact that 
multiple patients were unprepared for the physical invalida-
tion and long recovery time after surgery. It has been recog-
nized that information on cancer screening rarely provides 
details about potential negative outcomes [28]. Our results 
show that also in our program there is room for improvement 
in ensuring patients’ understanding of the surgical proce-
dure, the recovery process, and the pathological outcome. 
This is essential to help individuals make an informed deci-
sion regarding whether they opt for undergoing surveillance 
and surgery [27].
At the time of interviewing, despite the development of 
pancreatic exocrine insufficiency in the majority, all oper-
ated patients judged their health as “fair” or “good”, and 
quality of life scores were similar as age-matched reference 
data from the general population [24]. Post-surgery quality 
of life has not previously been reported for high-risk indi-
viduals in a pancreatic cancer surveillance program. Most 
studies have been performed in either pancreatic cancer or 
chronic pancreatitis patients, whose prospects and physical 
state are incomparable to our cohort. Other studies have 
reported on a more similar group, consisting of patients 
undergoing surgery for benign pancreatic disease other 
than chronic pancreatitis, and found similar results as ours, 
showing good quality-of-life scores that were not negatively 
impacted by surgery [35–38].
Several strengths and limitations of our study can be 
noted. The reliability of our results is assured by several 
methodical strengths. These include a prospective design 
and the use of validated tools to measure psychological bur-
den, which all showed good internal consistency. Further-
more, the semi-structured interviews yielded high response 
rates. In addition, there was a good-to-outstanding inter-rater 
agreement in the interpretation of the interviews, although 
the number of double-labelled interviews was relatively low 
and hence, this could partly be due to chance.
Although our surveillance program in individuals at 
high risk for pancreatic cancer is one of the largest in the 
world, the number of participants who had undergone inten-
sified surveillance and/or surgery was limited, and not all 
eligible individuals had returned questionnaires at all three 
time points. A larger eligible population would have made 
our results more robust and could have shown differences 
between groups that currently did not reach statistical sig-
nificance. Because the used interval during intensified sur-
veillance is often three months, this leaves a small window 
for the questionnaire to be sent out and returned. In order to 
keep the results valid, we excluded questionnaires with unre-
liable timing. We have overcome this limitation by includ-
ing all participants who returned a questionnaire at two 
of the three time points, and by performing the additional 
interviews. Ultimately, we were able to assess the impact of 
intensified surveillance in 74% of the eligible individuals. It 
has to be noted that, as we do not have data on the individu-
als who declined participation in the surveillance program, 
we should only extrapolate our results to individuals who 
undergo surveillance. Secondly, no specific validated ques-
tionnaire was available for our surgical patients. Although 
there are specific validated tools for patients operated for 
cancer, these do not apply to our cohort of individuals who 
are at risk, but do not have a cancer diagnosis. We used the 
SF-12, a more general validated tool to measure quality of 
life, with available normative data from the Dutch general 
population [23, 24]. A third limitation is the possible effect 
of a recall bias. As with all retrospective interviews, partici-
pants’ may be biased in their memories of an event several 
years prior, and their opinion may be more moderate than 
at the time of the event. To limit this, we restricted inclu-
sion to individuals who underwent an intensified surveil-
lance period a maximum of three years prior. Of the final 
eight participants, only two (25%) underwent intensified 
surveillance more than two years prior. Regarding the sur-
gical interviews, all surgical patients were invited, without 
restriction on the date of surgery. Because pancreatic sur-
gery can lead to permanent long-term co-morbidities (such 
as pancreatic exocrine insufficiency and insulin-dependent 
diabetes mellitus) which often require time to develop, it is 
not preferred to assess the impact of surgery shortly after 
the event.
In summary, the burden of intensified investigations 
within a surveillance program for individuals at high risk for 
pancreatic cancer seems tolerable. Overall, it did not influ-
ence the positive attitude of high-risk individuals towards 
the pancreatic cancer surveillance program, and the increase 
in cancer worries was transient and relatively modest. Our 
results suggest the burden of surgery is acceptable to high-
risk individuals undergoing pancreatic cancer surveillance, 
and perceived to be outweighed by the benefit of possible 
early detection and curation of pancreatic cancer. However, 
taking into account the associated morbidity and mortality 
of pancreatic surgery, the difficulty of correctly identifying 
high-risk lesions based on imaging, and that the majority of 
these so-called indeterminate lesions in our cohort eventu-
ally concerned irrelevant lesions, the decision to perform 
surgery should be carefully made after discussion within a 
multidisciplinary panel.
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